This study is currently recruiting participants.
National Heart, Lung and Blood Institute (NHLBI)
Type: Enrolling by Invitation Gender: Male & Female Min Age: 18 Years Max Age: N/A
Referral Letter Required
Adults who are or may become unable to consent
Longterm Follow-up; Natural History
Sickle Cell Disease
National Heart, Lung, and Blood Institute
In a previous study, people with sickle cell disease (SCD) were given LentiGlobin BB305. It is a gene transfer treatment. Researchers hoped that it could reduce or stop the symptoms of SCD. Researchers want to maintain long-term contact with the people from the study to follow their progress.
To monitor the long-term effects of the LentiGlobin BB305 treatment.
People with SCD who took part in the bluebird bio, Inc. protocol HGB-206, where LentiGlobin BB305 was used to treat SCD.
Participants will have a medical history and medicine review.
Participants will have periodic visits to NIH for 13 years.
Participants will have a physical exam. They will give blood and urine samples. They will be asked about their pain.
Participants will have magnetic resonance imaging (MRI) or magnetic resonance angiogram (MRA) of the brain. Those who are not able to have an MRI/MRA will have a CT scan. Participants age 16 and younger will have transcranial Doppler. These tests monitor and take pictures of the brain without going inside the body.
Participants will have an echocardiogram. It uses ultrasound to see the heart.
Participants will have an MRI or other image taken of their liver. It will be used to measure the level of iron in the liver and see if the iron has caused any damage to the liver.
Participants will complete surveys about how their SCD affects their quality of life, their cognitive function, and how they are feeling.
Participants may have a bone marrow biopsy.
--Back to Top--
INCLUSION CRITERIA: Subjects meeting the following criteria are eligible for study participation: 1. Provision of written informed consent for this study by subject, or as applicable, subject s parent(s)/ legal guardian(s) 2. Treated with drug product for therapy of SCD in a bluebird bio-sponsored clinical study EXCLUSION CRITERIA: There are no exclusion criteria for this study.
Subjects meeting the following criteria are eligible for study participation:
1. Provision of written informed consent for this study by subject, or as applicable, subject s parent(s)/ legal guardian(s)
2. Treated with drug product for therapy of SCD in a bluebird bio-sponsored clinical study
There are no exclusion criteria for this study.
For more information: